FIGURE 1
FROM:
Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo
M Wang, X H Han, L Zhang, J Yang, J F Qian, Y K Shi, L W Kwak, J Romaguera and Q Yi
BACK TO ARTICLEFigure 1.
Growth inhibitory effects of BTZ, CTX and RTX individually or in combination of three (the BRC regimen) on four MCL cell lines. (a) BTZ at concentrations of 0–80 nM, (b) RTX at concentrations of 0–10 
g ml-1, (c) CTX at concentrations of 0–20 mM and (d) BRC regimen with different concentrations of BTZ combined with a fixed concentration of RTX (10 g ml-1) and CTX (10 mM). BRC dose–response curves in the four MCL cell lines are steeper and shifted to the left, suggesting synergistic growth inhibition effects. Cell growth was measured in a 48-h culture using MTS assay. Results of three independent experiments are shown.